BR112022025542A2 - Compostos e seu uso como substâncias terapeuticamente ativas no tratamento e/ou prevenção de doenças envolvendo o epitélio pigmentado da retina - Google Patents

Compostos e seu uso como substâncias terapeuticamente ativas no tratamento e/ou prevenção de doenças envolvendo o epitélio pigmentado da retina

Info

Publication number
BR112022025542A2
BR112022025542A2 BR112022025542A BR112022025542A BR112022025542A2 BR 112022025542 A2 BR112022025542 A2 BR 112022025542A2 BR 112022025542 A BR112022025542 A BR 112022025542A BR 112022025542 A BR112022025542 A BR 112022025542A BR 112022025542 A2 BR112022025542 A2 BR 112022025542A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
compounds
active substances
therapeuticly
Prior art date
Application number
BR112022025542A
Other languages
English (en)
Inventor
Steger Matthias
Mueller Alex
Marigo Mauro
Original Assignee
Endogena Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endogena Therapeutics Inc filed Critical Endogena Therapeutics Inc
Publication of BR112022025542A2 publication Critical patent/BR112022025542A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTOS E SEU USO COMO SUBSTÂNCIAS TERAPEUTICAMENTE ATIVAS NO TRATAMENTO E/OU PREVENÇÃO DE DOENÇAS ENVOLVENDO O EPITÉLIO PIGMENTADO DA RETINA. A presente invenção refere-se a compostos e seu uso como substâncias terapeuticamente ativas no tratamento e/ou prevenção de doenças envolvendo o epitélio pigmentado da retina, e em particular no tratamento e/ou prevenção de doenças que levam à atrofia, degeneração ou morte do epitélio pigmentado da retina que também pode resultar em atrofia de fotorreceptores e/ou neovascularização da retina.
BR112022025542A 2020-06-19 2020-06-19 Compostos e seu uso como substâncias terapeuticamente ativas no tratamento e/ou prevenção de doenças envolvendo o epitélio pigmentado da retina BR112022025542A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/038715 WO2021257092A1 (en) 2020-06-19 2020-06-19 New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium

Publications (1)

Publication Number Publication Date
BR112022025542A2 true BR112022025542A2 (pt) 2023-01-17

Family

ID=79268235

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025542A BR112022025542A2 (pt) 2020-06-19 2020-06-19 Compostos e seu uso como substâncias terapeuticamente ativas no tratamento e/ou prevenção de doenças envolvendo o epitélio pigmentado da retina

Country Status (11)

Country Link
US (1) US20230322749A1 (pt)
EP (1) EP4167999A4 (pt)
JP (1) JP2023537814A (pt)
KR (1) KR20230027186A (pt)
CN (1) CN115916192A (pt)
AU (1) AU2020454040A1 (pt)
BR (1) BR112022025542A2 (pt)
CA (1) CA3183057A1 (pt)
IL (1) IL299160A (pt)
MX (1) MX2022016085A (pt)
WO (1) WO2021257092A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512997A (ja) * 1998-04-29 2002-05-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ｉｍｐｄｈ酵素のインヒビター
CN101310771B (zh) * 2001-04-11 2012-08-08 千寿制药株式会社 视觉功能障碍改善剂
WO2009079008A1 (en) * 2007-12-19 2009-06-25 Yangbo Feng Benzopyrans and analogs as rho kinase inhibitors
US20090325959A1 (en) * 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
CN114010788A (zh) * 2014-08-22 2022-02-08 奥克兰联合服务有限公司 通道调节剂
US10807973B2 (en) * 2018-12-28 2020-10-20 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases

Also Published As

Publication number Publication date
CN115916192A (zh) 2023-04-04
KR20230027186A (ko) 2023-02-27
AU2020454040A1 (en) 2023-02-09
IL299160A (en) 2023-02-01
EP4167999A4 (en) 2024-03-06
US20230322749A1 (en) 2023-10-12
EP4167999A1 (en) 2023-04-26
CA3183057A1 (en) 2021-12-23
WO2021257092A1 (en) 2021-12-23
MX2022016085A (es) 2023-02-02
JP2023537814A (ja) 2023-09-06

Similar Documents

Publication Publication Date Title
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112016025997A8 (pt) compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica
BR112022003999A2 (pt) Miméticos de hepcidina conjugados
van der Merwe et al. Endophthalmitis prophylaxis with intracameral cefuroxime in South Africa
BRPI0606172A2 (pt) métodos e composições para o tratamento de distúrbios oculares
BR112017023805A2 (pt) formulações de tpp1 e métodos para o tratamento de doença lcn2
WO2017070647A8 (en) Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma)
BR112018072127A2 (pt) inibidores de dipeptidil peptidase-4 para o tratamento ocular tópico de doenças neurodegenerativas da retina
MX2019008963A (es) Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico.
BR112021016296A2 (pt) Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112022011102A2 (pt) Tratamentos do edema macular diabético e da acuidade visual deficiente
BR112023013033A2 (pt) Regimes de tratamento com dexmedetomidina
Raghavan et al. Voriconazole in the successful management of a case of Acanthamoeba-Cladosporium keratitis
BR102019013368A8 (pt) Composições e métodos para tratamento de condições da pele usando luz e cloridrato de glicosamina
BR112022025542A2 (pt) Compostos e seu uso como substâncias terapeuticamente ativas no tratamento e/ou prevenção de doenças envolvendo o epitélio pigmentado da retina
BR112012015386B8 (pt) composição oftálmica tópica
BR112023023002A2 (pt) Regimes estendidos de antagonistas de vegf em altas doses para tratamento de doenças oculares angiogênicas
BR112022000417A2 (pt) Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmv
BR112023000455A2 (pt) Tratamento de doença inflamatória que usa anticorpos de fator antitecidual
BR112012023749A2 (pt) método para reduzir a pressão intraocular em humanos utilizando n6-ciclopentiladenosina (cpa), derivados de cpa ou pró-fármacos desses
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
CL2022003631A1 (es) Nuevos compuestos y su uso a manera de principios terapéuticamente activos en el tratamiento y/o prevención contra enfermedades relacionadas con el epitelio pigmentario retiniano.
BR112021000183A8 (pt) Preparação medicinal para uso externo
BR112022014925A8 (pt) Inibidores macrocíclicos de rip2-quinase